Relapse Following CAR T-cell Therapy Linked to Poor OS in Relapsed/Refractory Myeloma

August 27, 2022Lisa AstorRelapse following treatment with BCMA-directed CAR T-cell therapy was associated with poor survival outcomes in patients with relapsed/refractory multiple myeloma.Multiple Mye

Updated on: October 24,2023

Relapse Following CAR T-cell Therapy Linked to Poor OS in Relapsed/Refractory Myeloma

August 27, 2022Lisa AstorRelapse following treatment with BCMA-directed CAR T-cell therapy was associated with poor survival outcomes in patients with relapsed/refractory multiple myeloma.Multiple Mye

Updated on:October 24,2023

Camizestrant may be superior to fulvestrant in patients with hormone receptor-positive, HER2-negative breast cancer

byAmerican Association for Cancer ResearchCredit: Pixabay/CC0 Public DomainThe next-generation selective estrogen receptor degrader (SERD) camizestrant improved progression-free survival, compar

Updated on: December 21,2023

Camizestrant may be superior to fulvestrant in patients with hormone receptor-positive, HER2-negative breast cancer

byAmerican Association for Cancer ResearchCredit: Pixabay/CC0 Public DomainThe next-generation selective estrogen receptor degrader (SERD) camizestrant improved progression-free survival, compar

Updated on:December 21,2023

CAR T cell therapy for T cell lymphoma shows promise in phase I trial

by Molly Chiu,Baylor College of MedicineCredit: Pixabay/CC0 Public DomainResearchers at the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children's Hospital, and Hou

Updated on: January 26,2024

CAR T cell therapy for T cell lymphoma shows promise in phase I trial

by Molly Chiu,Baylor College of MedicineCredit: Pixabay/CC0 Public DomainResearchers at the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children's Hospital, and Hou

Updated on:January 26,2024

Curbing blood cancers by teaching immune cells to kill mutant stem cells

by Nancy Fliesler,Children's Hospital BostonROS and TLR3 signaling mediates the "eat-me" and "don't eat me" signals that determine stem cell clonal selection by macro

Updated on: October 24,2024

Curbing blood cancers by teaching immune cells to kill mutant stem cells

by Nancy Fliesler,Children's Hospital BostonROS and TLR3 signaling mediates the "eat-me" and "don't eat me" signals that determine stem cell clonal selection by macro

Updated on:October 24,2024

Deaths from advanced lung cancer have dropped significantly since immunotherapy became standard-of-care

byWileyCredit: Unsplash/CC0 Public DomainSince the first immunotherapy drug to boost the body's immune response against advanced lung cancer was introduced in the United States in 2015, surv

Updated on: August 27,2024

Deaths from advanced lung cancer have dropped significantly since immunotherapy became standard-of-care

byWileyCredit: Unsplash/CC0 Public DomainSince the first immunotherapy drug to boost the body's immune response against advanced lung cancer was introduced in the United States in 2015, surv

Updated on:August 27,2024

Using a machine learning algorithm with cancer methylation signatures to diagnose colorectal cancer

by Bob Yirka , Medical XpressCancer—Histopathologic image of colonic carcinoid. Credit: Wikipedia/CC BY-SA 3.0A team of researchers affiliated with a large number of institutions in China has used a m

Updated on: December 20,2023

Using a machine learning algorithm with cancer methylation signatures to diagnose colorectal cancer

by Bob Yirka , Medical XpressCancer—Histopathologic image of colonic carcinoid. Credit: Wikipedia/CC BY-SA 3.0A team of researchers affiliated with a large number of institutions in China has used a m

Updated on:December 20,2023

Ultrafine particles can change defense against lung cancer

by Graciela Gutierrez,Baylor College of MedicinenCB accelerates NSCLC development and metastasis in mice. (A) Schematic diagram of nCB exposure in Pts4d/dmice. Three-month-old Pts4d/d&nbsp

Updated on: December 19,2023

Ultrafine particles can change defense against lung cancer

by Graciela Gutierrez,Baylor College of MedicinenCB accelerates NSCLC development and metastasis in mice. (A) Schematic diagram of nCB exposure in Pts4d/dmice. Three-month-old Pts4d/d&nbsp

Updated on:December 19,2023

Step-by-Step "Blood Replacement": A New ADC Therapy for Precise Tumor Elimination

Updated on: May 29,2024

Step-by-Step "Blood Replacement": A New ADC Therapy for Precise Tumor Elimination

Updated on:May 29,2024

Cancer cells hijack enhancer DNA to grow faster, study finds

University of Toronto (U of T) researchers have found that cancer cells can enhance tumor growth by hijacking enhancer DNA normally used when tissues and organs are formed. The mechanism, called enhan

Updated on: October 30,2023

Cancer cells hijack enhancer DNA to grow faster, study finds

University of Toronto (U of T) researchers have found that cancer cells can enhance tumor growth by hijacking enhancer DNA normally used when tissues and organs are formed. The mechanism, called enhan

Updated on:October 30,2023

Unique gene signature could help predict response to chemotherapy

byThe Francis Crick InstituteIn vitro anticancer drug screen. a Volcano plots showing differences in IC50 values between RAS high and low CCLE cell lines. Drugs with enriched target annotations

Updated on: December 20,2023

Unique gene signature could help predict response to chemotherapy

byThe Francis Crick InstituteIn vitro anticancer drug screen. a Volcano plots showing differences in IC50 values between RAS high and low CCLE cell lines. Drugs with enriched target annotations

Updated on:December 20,2023

Immunotherapy improves survival in metastatic or recurrent head and neck cancer

byEuropean Society for Medical OncologyProf Barbara Burtness, Yale School of Medicine and Co-Director, Development Therapeutics Research Program, Yale Cancer Center, New Haven, US, study author.

Updated on: December 18,2023

Immunotherapy improves survival in metastatic or recurrent head and neck cancer

byEuropean Society for Medical OncologyProf Barbara Burtness, Yale School of Medicine and Co-Director, Development Therapeutics Research Program, Yale Cancer Center, New Haven, US, study author.

Updated on:December 18,2023

Study of rare cancer identifies patients at highest risk of metastasis and those who would respond to immunotherapy

byThe Spanish National Cancer Research CentreCNIO researchers Bruna Calsina (left) and Mercedes Robledo. Credit: Laura M. Lombardía, CNIOPheochromocytoma is a rare tumor, with an incidence of th

Updated on: December 23,2023

Study of rare cancer identifies patients at highest risk of metastasis and those who would respond to immunotherapy

byThe Spanish National Cancer Research CentreCNIO researchers Bruna Calsina (left) and Mercedes Robledo. Credit: Laura M. Lombardía, CNIOPheochromocytoma is a rare tumor, with an incidence of th

Updated on:December 23,2023